Our top pick for
Akero Therapeutics, Inc is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Akero Therapeutics employs 16 staff and has a market cap (total outstanding shares value) of USD$905.2 million.
|Latest market close||USD$29.11|
|52-week range||USD$10.78 - USD$41.16|
|50-day moving average||USD$28.0809|
|200-day moving average||USD$30.8612|
|Wall St. target price||USD$60.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-91.753|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||15.98%|
|1 month (2020-12-17)||8.50%|
|3 months (2020-10-16)||2.68%|
|6 months (2020-07-16)||-21.96%|
|1 year (2020-01-16)||47.84%|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing Akero Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akero Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akero Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Akero Therapeutics shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-18.49%|
|Return on equity TTM||-30.29%|
|Market capitalisation||USD$905.2 million|
TTM: trailing 12 months
There are currently 1.9 million Akero Therapeutics shares held short by investors – that's known as Akero Therapeutics's "short interest". This figure is 5.8% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Akero Therapeutics shares can be evaluated.
Akero Therapeutics's "short interest ratio" (SIR) is the quantity of Akero Therapeutics shares currently shorted divided by the average quantity of Akero Therapeutics shares traded daily (recently around 151579.12698413). Akero Therapeutics's SIR currently stands at 12.6. In other words for every 100,000 Akero Therapeutics shares traded daily on the market, roughly 12600 shares are currently held short.
However Akero Therapeutics's short interest can also be evaluated against the total number of Akero Therapeutics shares, or, against the total number of tradable Akero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akero Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Akero Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1003% of the tradable shares (for every 100,000 tradable Akero Therapeutics shares, roughly 100 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akero Therapeutics.
Find out more about how you can short Akero Therapeutics stock.
We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.